Neurocrine Biosciences
NBIX
#1366
Rank
HK$120.70 B
Marketcap
HK$1,211
Share price
0.84%
Change (1 day)
21.43%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Neurocrine Biosciences (NBIX) - Total debt

Total debt on the balance sheet as of September 2025 : HK$3.33 Billion

According to Neurocrine Biosciences 's latest financial reports the company's total debt is HK$3.33 Billion. A companyโ€™s total debt is the sum of all current and non-current debts.

Neurocrine Biosciences - Total debt on balance sheet (from 1996 to 2025)

Total debt by year

Year Total debt Change
2024-12-31HK$3.53 B5.6%
2023-12-31HK$3.34 B62.88%
2022-12-31HK$2.05 B-40.18%
2021-12-31HK$3.43 B7.44%
2020-12-31HK$3.19 B-17.17%
2019-12-31HK$3.85 B26.85%
2018-12-31HK$3.04 B5.35%
2017-12-31HK$2.88 B
2009-12-31HK$89.4 M-24.86%
2008-12-31HK$0.11 B926.9%
2007-12-31HK$11.58 M-97.22%
2006-12-31HK$0.41 B-9.42%
2005-12-31HK$0.46 B-10.37%
2004-12-31HK$0.51 B81.97%
2003-12-31HK$0.28 B356.36%
2002-12-31HK$61.88 M39.54%
2001-12-31HK$44.34 M46.92%
2000-12-31HK$30.18 M25.33%
1999-12-31HK$24.08 M3.62%
1998-12-31HK$23.24 M87.45%
1997-12-31HK$12.39 M0.19%
1996-12-31HK$12.37 M

Total debt for similar companies or competitors

Company Total debt/th> differencediff. Country
Repligen
RGEN
HK$5.36 B 60.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
HK$69.63 B 1,988.17%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
HK$2.04 M-99.94%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
HK$330.89 B 9,822.18%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
HK$535.13 B 15,946.45%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
HK$473.67 B 14,103.55%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
HK$4.82 B 44.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
HK$0.14 B-95.66%๐Ÿ‡บ๐Ÿ‡ธ USA